We encourage regular surveillance by clinicians and pharmacovigilance experts on these drugs, including the third-generation agent tivozanib (higher selectivity towards VEGFR and favorable pharmacokinetics), recently approved for advanced renal cell carcinoma and under additional regulatory monitoring. This evidence concerns the gene KDR and hereditary clear cell renal cell carcinoma.